Success Story: EB1A Approved After RFE for Major Contributions in Neuropsychiatry and Early Dementia Detection
Client’s Testimonial:
“Thank you for all your support throughout the process!”
On December 19th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Fellow in the Field of Cognitive Neuroscience (Approval Notice).
General Field: Cognitive Neuroscience
Position at the Time of Case Filing: Research Fellow
Country of Origin: Germany
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: December 19th, 2025
Processing Time: 3 months, 22 days (Premium Processing Requested)
Case Summary:
In neuropsychiatry, the most meaningful breakthroughs are often the ones that make complex brain changes visible earlier and more clearly, before symptoms become irreversible. In this case, a research fellow built a research program that connects cognitive neuroscience to real clinical questions, including how to identify biomarkers that strengthen early dementia diagnosis and guide the next generation of diagnostic strategies. The EB1A petition was filed with premium processing on August 27, 2025, and the case ultimately earned approval on December 19, 2025.
USCIS issued an RFE on September 15, 2025, focusing the adjudication on a familiar EB1A pressure point: whether the client’s work rose to the level of original contributions of major significance. North America Immigration Law Group (Chen Immigration Law Associates) treated the response as a translation task, converting technical influence into adjudicator-readable proof through third-party reliance, comparative citation context, and concrete examples of how independent researchers used the client’s findings to push their own projects forward.
The client’s profile supported that argument with depth and consistency. With a Ph.D. in Experimental Psychology, he developed a sustained publication record in cognitive neuroscience and neuropsychiatry, including 35 peer-reviewed journal articles (with 8 first-authored) and 8 abstracts (with 3 first-authored). His work drew wide research attention, reflected in 610 citations at the time of filing, alongside repeated invitations to serve as a gatekeeper for the field through at least 51 peer reviews for journals.
Funding further reinforced the seriousness and real-world relevance of the research direction. The client’s work was supported by major institutions and foundations, including the National Institutes of Health (NIH), the National Institute of Mental Health (NIMH), the Larry L. Hillblom Foundation, the Brain and Behavior Research (BBR) Foundation, the BIAL Foundation, and other competitive programs. Taken together, this support helped show that multiple respected funders considered the work important enough to back, and that the client was operating at a level where sustained research investment follows demonstrated value.
One recommender captured the practical significance of the client’s dementia-related contributions by noting:
"Not only has [Client] identified effective biomarkers for early dementia diagnosis, but these groundbreaking findings are also invaluable for continuing research, thereby providing a new foundation for developing earlier and more effective diagnostic strategies for dementia."
With a focused RFE response and premium processing in place, USCIS approved the EB1A on December 19, 2025, bringing the total processing time to 3 months, 22 days, and confirming that the evidence met both the criteria and the final merits determination standard.